학술논문

Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study
Document Type
Article
Source
In: The Lancet. (The Lancet, 30 September 2023, 402(10408):1133-1146)
Subject
Language
English
ISSN
1474547X
01406736